G Protein News and Research

RSS

NIH renews grant to continue cell growth regulation research

The new year began on a high note for Alan Leonard and Julia Grimwade, professors of biological sciences at Florida Institute of Technology, when they learned their National Institutes of Health grant, which they have held for the last 11 years, had been renewed for four more years. The competitive renewal brings them $1,024, 944 to continue their research into the regulation of cell growth and division.

11 Jan 2010

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Research into "chemical chaperone" may lead to new treatments for heart attacks

Researchers at the Indiana University and Stanford University schools of medicine have determined how a "chemical chaperone" does its job in the body, which could lead to a new class of drugs to help reduce the muscle damage caused by heart attacks.

10 Jan 2010

Gene therapy may help correct molecular flaws that cause brain disease

Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system.

9 Jan 2010

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

Scientific societies to hold Experimental Biology 2010 meeting

Six scientific societies announced they will hold their annual meeting, Experimental Biology (EB 2010; www.experimentalbiology.org), April 24-28, 2010 in Anaheim, CA. The societies are the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and American Society for Pharmacology and Experimental Therapeutics (ASPET).

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

Pall introduces new prepacked chromatography columns for faster protein purification process

Pall Corporation, a global leader in filtration, separation and purification, announces the launch of 5 mL PRC prepacked chromatography columns to deliver faster and more consistent protein purification processing.

From Pall Corporation 8 Jan 2010

CSHL scientists explain how initiation of DNA replication is coordinated and controlled by kinase proteins

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.

8 Jan 2010

NEB introduces Lemo21(DE3) Competent E. coli

New England Biolabs (NEB) has introduced Lemo21(DE3) Competent E. coli, a tunable T7 expression strain optimized for the expression of difficult constructs, including membrane proteins, toxic proteins and proteins prone to insoluble expression.

From New England Biolabs 8 Jan 2010

Variants in CRP gene not associated with increased risk of cancer

Gene variants associated with increased circulating levels of C-reactive protein, a marker of inflammation, are not associated with an increased risk of cancer, according to a new brief communication published online January 7 in the Journal of the National Cancer Institute.

8 Jan 2010

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine.

8 Jan 2010

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

G Protein News and Research

NIH renews grant to continue cell growth regulation research

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

New technique may help researchers to test amyloid hypothesis in AD development

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Research into "chemical chaperone" may lead to new treatments for heart attacks

Gene therapy may help correct molecular flaws that cause brain disease

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Scientific societies to hold Experimental Biology 2010 meeting

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Cancer Research UK scientists named on New Year's Honours list

Pall introduces new prepacked chromatography columns for faster protein purification process

CSHL scientists explain how initiation of DNA replication is coordinated and controlled by kinase proteins

NEB introduces Lemo21(DE3) Competent E. coli

Variants in CRP gene not associated with increased risk of cancer

Proteostasis Therapeutics enters into exclusive license agreement with New York University

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News